Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Setmelanotide demonstrated a significant reduction in weight, with a mean difference of -3.52 (95% confidence interval (CI) -3.98, -3.05) and an average weight loss of -6.91% in patients with severe obesity linked to melanocortin 4 receptor (MC4R) deficiency.
• There was a marked decrease in body mass index (BMI), particularly in adults (>18 years), with a mean reduction of -10.55 kg/m², while children (<18 years) saw a smaller BMI decrease of -0.61 kg/m².
• Skin hyperpigmentation was observed as a potential adverse effect, with an odds ratio of 0.69 (95% CI 0.55, 0.80), though it did not reach statistical significance (p = 0.08).
• There were no other significant adverse safety outcomes highlighted in the reviewed studies.
• Setmelanotide demonstrated a more significant reduction in BMI in adults (>18 years old) with a mean difference of -10.55 kg/m² compared to children (<18 years old) with a smaller BMI reduction of -0.61 kg/m², indicating that the drug may be more effective in adults. There is no further information on specific subgroups.